OGEN - Oragenics jumps 14% on licensing deal for intranasal covid vaccine candidate
- Oragenics ( NYSE: OGEN ) shares rise 14% after the company entered into an exclusive global license agreement with Inspirevax for its novel intranasal mucosal adjuvant, BDX301, for the development of NT-CoV2-1, Oragenics’ lead intranasal COVID-19 vaccine candidate.
- Under the agreement, OGEN will pursue the development of NT-CoV2-1 with Inspirevax’s BDX301 intranasal mucosal adjuvant.
- Oragenics will make clinical, regulatory and commercial milestone payments, as well as tiered royalty payments. Additionally, the agreement provides a certain period of time for the companies to expand their collaboration to pursue the development of additional intranasal vaccine candidates using Inspirevax’s adjuvants.
For further details see:
Oragenics jumps 14% on licensing deal for intranasal covid vaccine candidate